SCHEMBL6784877

SCHEMBL6784877

C/C(=C/C(=O)Nc1cc2c(cc1C(=O)O)OCO2)c1ccc2ccccc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.70
ALDH1A1 P00352 5/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 5/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 1/20 0.45
CASP1 P29466 1/20 0.44
LTB4R Q15722 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
TDP1 Q9NUW8 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784154 0.89 TERT (0.58) TERTALDH1A1GAAHPGDKDM4E
SCHEMBL6783614 0.87 TERT (0.81) TERTALDH1A1HPGDKDM4EHSD17B10
SCHEMBL19554230 0.84 PTGS2 (0.58) ALDH1A1GAAHPGDKDM4ESMN1; SMN2
SCHEMBL4024629 0.83 TERT (0.74) TERTKDM4ELTB4RNPC1RAB9A
SCHEMBL6783732 0.83 TERT (0.85) TERTKDM4EHSD17B10LTB4RNPC1
SCHEMBL30760782 0.83 TERT (1.00) TERTALDH1A1KDM4ELTB4RNPC1
SCHEMBL29362821 0.83 TERT (1.00) TERTALDH1A1KDM4ELTB4RNPC1
SCHEMBL29966843 0.83 TERT (1.00) TERTALDH1A1KDM4ELTB4RNPC1
SCHEMBL16964998 0.83 TERT (1.00) TERTALDH1A1KDM4ELTB4RNPC1
SCHEMBL4022937 0.83 TERT (1.00) TERTALDH1A1KDM4ELTB4RNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885ALDH1A1 102/4885GAA 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.